CALC

CalciMedica, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website calcimedica.com
Employees(FY) 14
ISIN US38942Q2021

Performance

-1.15%

-15.44%

-17.86%

-36.7%

+20.63%

YTD

+10.42%

Profile

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Advanced Technical Analysis

Technical Analysis of CALC 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 16 indicating strong bearish momentum, while the Technical Score of 33 further supports this outlook. The Oscillators Score of 50 suggests a neutral position, but it does not outweigh the prevailing bearish signals from the other indicators.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CALC

Stock Rank

Recent News & Updates

2024-11-12 18:00
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates(Prnewswire)
2024-11-06 18:00
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer(Prnewswire)
2024-10-30 10:11
CalciMedica Announces Pricing of Public Offering of Common Stock(Prnewswire)
2024-10-30 04:50
CalciMedica Announces Proposed Public Offering of Common Stock(Prnewswire)
2024-10-29 19:00
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting(Prnewswire)
2024-10-28 04:05
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)(Prnewswire)
2024-10-15 20:00
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting(Prnewswire)
2024-09-02 20:00
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-12 04:10
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates(Prnewswire)
2024-07-08 19:30
CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora in Severe Acute Kidney Injury (AKI)(Prnewswire)
2024-07-07 20:00
CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences(Prnewswire)
2024-06-30 20:00
CalciMedica Set to Join Russell Microcap Index(Prnewswire)
2024-06-26 20:00
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)(Prnewswire)
2024-06-26 19:06
CalciMedica's calcium channel inhibitor helps subgroup of pancreatitis patients eat solids sooner(Fiercebiotech)
2024-06-26 04:05
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora in Acute Pancreatitis (AP)(Prnewswire)
2024-05-27 19:53
CALC Stock Earnings: CalciMedica Beats EPS for Q1 2024(Investorplace)
2024-05-20 21:48
3 Massively Undervalued 10-Bagger Stocks to Buy(Investorplace)
2024-05-13 04:05
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates(Prnewswire)
2024-05-06 20:00
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024(Prnewswire)
2024-04-23 20:00
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora in Acute Pancreatitis(Prnewswire)
2024-04-10 03:30
Insiders are Piling into These 10 Healthcare Stocks in 2024(Insidermonkey)
2024-03-27 23:53
CALC Stock Earnings: CalciMedica Reported Results for Q4 2023(Investorplace)
2024-03-27 19:00
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates(Prnewswire)
2024-03-12 20:00
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference(Prnewswire)
2024-02-28 05:57
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference(Yahoo Finance)
2024-02-12 19:00
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora for the Treatment of Severe Acute Kidney Injury(Prnewswire)
2024-02-07 03:05
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference(Prnewswire)
2024-01-21 19:00
CalciMedica Announces Private Placement of up to Approximately $55 Million(Prnewswire)
2023-12-10 18:30
CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition(Prnewswire)
2023-11-08 18:00
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates(Prnewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.